Iovance raises FY 2026 total revenue guidance to $410 million-$420 million

Iovance Biotherapeutics lifted full-year 2026 total revenue guidance to $410 million-$420 million from $350 million-$370 million, citing strong U.S. demand for Amtagvi and Proleukin. Second-quarter 2026 total product revenue hit a record $99.3 million.